What is the appropriate management plan for a patient with a history of osteomyelitis who is currently stable, on apixaban (Eliquis) for stroke/TIA prophylaxis, and has no signs of active infection?

Management Plan for Stable Osteomyelitis Patient on Apixaban

Continue apixaban without interruption for stroke/TIA prophylaxis, monitor for signs of infection recurrence, and maintain clinical surveillance without routine antibiotic therapy in the absence of active infection. 1

Anticoagulation Management

Your patient's apixaban should be maintained at the current dose without modification, as there is no active infection requiring surgical intervention that would necessitate temporary discontinuation. The FDA labeling for apixaban specifies that discontinuation is only required 24-48 hours prior to elective surgery or invasive procedures with bleeding risk 1. Since your patient is stable without active infection, no procedural intervention is imminent.

Key dosing considerations:

• If the patient is on 5 mg twice daily for stroke prevention, continue this dose
• If the patient meets dose reduction criteria (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL with at least 2 of these factors), the appropriate dose is 2.5 mg twice daily 1
• Recent evidence supports that apixaban can be safely continued even in complex clinical scenarios, with very low rates of symptomatic hemorrhagic complications 2, 3

Infection Surveillance Strategy

Without signs of active infection, no antibiotic therapy is indicated. The patient requires clinical monitoring rather than empirical treatment:

• Clinical assessment: Monitor for fever, new or worsening bone pain, soft tissue swelling, drainage, or systemic symptoms
• Laboratory markers: Periodic inflammatory markers (ESR, CRP) can help detect subclinical recurrence, though frequency should be individualized based on osteomyelitis history and risk factors
• Imaging considerations: MRI is the gold standard for detecting osteomyelitis recurrence and should be obtained if clinical suspicion arises 4

When to Intervene

Restart workup and treatment only if:

• New constitutional symptoms (fever, malaise)
• Recurrent pain at the previous infection site
• Visible drainage or soft tissue changes
• Elevated inflammatory markers with clinical correlation

If infection recurrence is suspected, the diagnostic approach depends on anatomical location 4:

With ulcer or sinus tract present:

• Obtain wound cultures from tissues closest to bone (avoid superficial swabs due to contamination risk)
• Bedside sampling is acceptable for identifying causative organisms 4

Without ulcer or sinus tract:

• Obtain MRI first
• If MRI positive for osteomyelitis, proceed to percutaneous image-guided bone biopsy for culture and targeted antibiotic therapy 4
• Negative MRI effectively rules out osteomyelitis and obviates need for biopsy 4

Critical Pitfalls to Avoid

Do not empirically treat with antibiotics in the absence of active infection. Chronic osteomyelitis without current activity does not require suppressive therapy, and inappropriate antibiotic use promotes resistance 5. The most common pathogen in osteomyelitis recurrence is Staphylococcus aureus (including MRSA), but treatment should be culture-directed whenever possible 5, 6.

Do not discontinue apixaban without a specific procedural indication. The stroke/TIA risk from atrial fibrillation outweighs theoretical bleeding concerns in a stable patient 1, 3. One case report describes osteomyelitis following nasal packing in an apixaban patient, but this was related to the packing procedure itself, not the anticoagulant 7.

Surgical Considerations

If infection recurs, surgical intervention may be necessary. In that scenario 1:

• Discontinue apixaban 24-48 hours before surgery (24 hours for low bleeding risk procedures, 48 hours for moderate-high risk)
• Bridging anticoagulation is generally not required during this brief interruption
• Restart apixaban once adequate hemostasis is established postoperatively

Chronic osteomyelitis with bone necrosis typically requires surgical debridement in addition to prolonged antibiotics (≥4-6 weeks), whereas acute hematogenous osteomyelitis can often be treated with antibiotics alone 8.